HomeNewsBusinessIs this the end of IndiGo promoters’ feud?

Is this the end of IndiGo promoters’ feud?

The two largest shareholders, Rahul Bhatia and Rakesh Gangwal, have convened an EGM to present a resolution that removes restrictions on the transfer of promoter shares, among other things. If it is accepted, it would end the dispute between the two.

December 30, 2021 / 17:15 IST
Story continues below Advertisement

InterGlobe Aviation Ltd, which operates India’s largest low-cost carrier (LCC) IndiGo, has faced turbulence for over two years due to the feud between the promoters but the upcoming shareholders’ meet on December 30 could potentially make way for a smooth flight.

IndiGo’s two largest shareholders, Rahul Bhatia and Rakesh Gangwal, who collectively hold 74.44 percent of the paid-up equity share capital have called an extraordinary general meeting (EGM) on Thursday to amend its Articles of Association (AoA) and remove restrictions on the transfer of promoter shares. If the resolution is accepted, it would end the dispute between the owners.

Story continues below Advertisement

The resolution is expected to pass smoothly, given that both the promoters have jointly called the meeting. Once passed, it would allow either side to sell or transfer shares to a third party, without giving each other notice.

While neither party has publicly said that they intend to sell their shares in IndiGo, the resolution would allow both promoters a chance to exit the airline. There are already speculations that Gangwal may dilute his stake. 

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show